Skip to main content
S 993 118th Congress Senate Crime and Law Enforcement Congressional oversight Criminal procedure and sentencing Drug trafficking and controlled substances Manufacturing Retail and wholesale trades Veterinary medicine and animal diseases

Combating Illicit Xylazine Act

Introduced: March 28, 2023 Introduced by: Cortez Masto, Catherine Democratic · Nevada See on congress.gov
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jan 11, 2024
Committee on Banking, Housing, and Urban Affairs. Hearings held.
Mar 28, 2023
Read twice and referred to the Committee on the Judiciary.
Mar 28, 2023
Introduced in Senate
 Plain-English summary Congressional Research Service

Combating Illicit Xylazine Act

This bill criminalizes the illicit use of xylazine. (Xylazine, also known as Tranq, is a sedative that is approved for use in animals. The Drug Enforcement Administration (DEA) has reported an increase in the trafficking of fentanyl mixed with xylazine.)

Specifically, the bill establishes criminal penalties for manufacturing, distributing, or dispensing, or possessing with intent to manufacture, distribute, or dispense, xylazine for illicit use (i.e., for use in humans) in accordance with the penalties for schedule III substances (up to 10 years imprisonment or, if death or serious bodily injury occurs, up to 15 years imprisonment, as well as criminal fines).

In addition, the DEA must coordinate with the Food and Drug Administration to report on the prevalence of the illicit use of xylazine, including associated supply chains. The bill also declares the illicit use of xylazine as an emerging drug threat.

What's happening now January 11, 2024

Committee on Banking, Housing, and Urban Affairs. Hearings held.